Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR443] to ARF1+ARF3 - BSA and Azide free
  • Suitable for: ICC, IHC-P, WB
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free
    See all ARF1+ARF3 primary antibodies

  • Description

    Rabbit monoclonal [EPR443] to ARF1+ARF3 - BSA and Azide free

  • Host species

    Rabbit

  • Specificity

    The immunogen used to raise this antibody shares 100% homology with human ARF3, 96% homology with ARF4 and ARF5, and 88% homology with ARF6. Cross-reactivity with the latter three proteins have not been confirmed experimentally.

  • Tested applications

    Suitable for: ICC, IHC-P, WBmore details
    Unsuitable for: Flow Cyt or IP

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • General notes

    Ab247639 is the carrier-free version of ab108347. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab247639 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Western blot - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    All lanes : Anti-ARF1 + ARF3 antibody [EPR443] (ab108347) at 1/50000 dilution

    Lane 1 : Full length human ARF-1 recombinant protein
    Lane 2 : Full length human ARF-3 recombinant protein

    Lysates/proteins at 0.015 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 21 kDa
    Observed band size: 23 kDa
    why is the actual band size different from the predicted?


    Exposure time: 3 minutes


    This data was developed using ab108347, the same antibody clone in a different buffer formulation.

    Blocking and dilution buffer: 5% NFDM/TBST.

    Human ARF-1 recombinant protein (ab123538), Human ARF-3 recombinant protein (ab113581).

  • Immunocytochemistry - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Immunocytochemistry - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    This data was developed using ab108347, the same antibody clone in a different buffer formulation.ICC/IF image of ab108347 stained CaCo2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab108347 at 1/100 dilution overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
  • Western blot - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Western blot - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    All lanes : Anti-ARF1 + ARF3 antibody [EPR443] (ab108347) at 1/1000 dilution

    Lane 1 : Human fetal kidney tissue lysate
    Lane 2 : Human fetal brain tissue lysate
    Lane 3 : MCF7 cell lysate

    Lysates/proteins at 10 µg per lane.

    Predicted band size: 21 kDa



    This data was developed using ab108347, the same antibody clone in a different buffer formulation.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    This data was developed using ab108347, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of ARF1 in paraffin embedded Human breast ductal carcinoma tissue, using ab108347 at a dilution of 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    This data was developed using ab108347, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of ARF1 in paraffin embedded Human colonic adenocarcinoma tissue, using ab108347 at a dilution of 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)
    Anti-ARF1+ARF3 antibody [EPR443] - BSA and Azide free (ab247639)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.